FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896020168> ?p ?o ?g. }

• W2896020168 endingPage "e315" @default.
• W2896020168 startingPage "e315" @default.
• W2896020168 abstract "The adaptive and innate immune system play a critical role in tumor control. Methods to improve the anti-tumor immune response through T-cell-specific therapies is the current focus of Immuno-Oncology. Our group and others have demonstrated that treatment-induced lymphopenia correlates with poorer prognosis in newly diagnosed glioblastoma (GBM) patients. We hypothesized that granulocytes, including neutrophils and eosinophils, influence the immunologic response to chemoradiation therapy (CRT) and patient outcomes. We conducted a single-institution, retrospective analysis of 94 patients diagnosed with WHO Grade IV GBM between 2011-2016 treated with surgery followed by CRT (60Gy in 30 fractions, temozolomide 75mg/m2/day) and adjuvant temozolomide. We evaluated the immunologic response to therapy through monthly complete blood count with differential for up to 3 months after CRT. On univariate analysis, the use of immunosuppressive steroids negatively correlated with overall survival (Pearson’s r = -0.382, p<0.01). White blood cell (WBC) count and absolute neutrophil count (ANC) measured at the end, 1 and 2 months after CRT also negatively correlated (r = -0.226 to -0.342, p<0.05) with overall survival. Whereas, eosinophil count measured at the end, 1, 2 and 3 months after CRT (r = 0.227 to 0.366, p<0.05) and absolute lymphocyte count (ALC) measured 3 months after CRT (r = 0.268, p<0.05) positively correlated with overall survival. On partial least squared regression, steroid use and eosinophil count 3 months after CRT were the 1st and 2nd variables of importance in the projection (VIP). In a multivariate analysis, steroid use and eosinophil count 3 months after CRT remained statistically significant (F=5.4, F=6.8, p<0.05). Kaplan-Meier analysis demonstrated that patients with a persistently increased eosinophil count (> 150 cells/uL) 3 months after CRT lived 45% longer than patients with lower (<150 cells/uL) eosinophil count (1165 (CI 663-942) vs. 802 (CI 973-1356) days, p=0.05). Cox regression analysis of patients treated with steroids > or < 59 days confirmed that increased steroid use correlated a 35% decrease in overall survival (639 (CI 513-759) vs. 988 (856-1121) days, p<0.01), independent of initial performance status. We demonstrate that treatment-induced increase in eosinophil count is the strongest hematologic predictor of overall survival in newly diagnosed GBM. Eosinophil count may serve as a proxy for immunologic response to therapy and thus yield more prognostic insight than ALC. We also demonstrate that independent of initial performance status, steroid use was associated with a decrease in overall survival. Though prospective studies are needed, these data suggest that use of immunosuppressive steroids should thus be used judiciously and discontinued when clinically possible." @default.
• W2896020168 created "2018-10-26" @default.
• W2896020168 creator A5009447848 @default.
• W2896020168 creator A5020418338 @default.
• W2896020168 creator A5022549128 @default.
• W2896020168 creator A5034940529 @default.
• W2896020168 creator A5051058729 @default.
• W2896020168 creator A5068619501 @default.
• W2896020168 creator A5082862247 @default.
• W2896020168 date "2018-11-01" @default.
• W2896020168 modified "2023-10-01" @default.
• W2896020168 title "Treatment-Induced Increase in Eosinophil Count is Associated with Improved Overall Survival in Glioblastoma patients" @default.
• W2896020168 doi "https://doi.org/10.1016/j.ijrobp.2018.07.981" @default.
• W2896020168 hasPublicationYear "2018" @default.
• W2896020168 type Work @default.
• W2896020168 sameAs 2896020168 @default.
• W2896020168 citedByCount "3" @default.
• W2896020168 countsByYear W28960201682020 @default.
• W2896020168 countsByYear W28960201682021 @default.
• W2896020168 crossrefType "journal-article" @default.
• W2896020168 hasAuthorship W2896020168A5009447848 @default.
• W2896020168 hasAuthorship W2896020168A5020418338 @default.
• W2896020168 hasAuthorship W2896020168A5022549128 @default.
• W2896020168 hasAuthorship W2896020168A5034940529 @default.
• W2896020168 hasAuthorship W2896020168A5051058729 @default.
• W2896020168 hasAuthorship W2896020168A5068619501 @default.
• W2896020168 hasAuthorship W2896020168A5082862247 @default.
• W2896020168 hasConcept C126322002 @default.
• W2896020168 hasConcept C143998085 @default.
• W2896020168 hasConcept C144301174 @default.
• W2896020168 hasConcept C2776042228 @default.
• W2896020168 hasConcept C2776376844 @default.
• W2896020168 hasConcept C2776694085 @default.
• W2896020168 hasConcept C2777037409 @default.
• W2896020168 hasConcept C2777063308 @default.
• W2896020168 hasConcept C2777389519 @default.
• W2896020168 hasConcept C2777761686 @default.
• W2896020168 hasConcept C2778488018 @default.
• W2896020168 hasConcept C2778963024 @default.
• W2896020168 hasConcept C38180746 @default.
• W2896020168 hasConcept C71924100 @default.
• W2896020168 hasConcept C74133956 @default.
• W2896020168 hasConcept C90924648 @default.
• W2896020168 hasConceptScore W2896020168C126322002 @default.
• W2896020168 hasConceptScore W2896020168C143998085 @default.
• W2896020168 hasConceptScore W2896020168C144301174 @default.
• W2896020168 hasConceptScore W2896020168C2776042228 @default.
• W2896020168 hasConceptScore W2896020168C2776376844 @default.
• W2896020168 hasConceptScore W2896020168C2776694085 @default.
• W2896020168 hasConceptScore W2896020168C2777037409 @default.
• W2896020168 hasConceptScore W2896020168C2777063308 @default.
• W2896020168 hasConceptScore W2896020168C2777389519 @default.
• W2896020168 hasConceptScore W2896020168C2777761686 @default.
• W2896020168 hasConceptScore W2896020168C2778488018 @default.
• W2896020168 hasConceptScore W2896020168C2778963024 @default.
• W2896020168 hasConceptScore W2896020168C38180746 @default.
• W2896020168 hasConceptScore W2896020168C71924100 @default.
• W2896020168 hasConceptScore W2896020168C74133956 @default.
• W2896020168 hasConceptScore W2896020168C90924648 @default.
• W2896020168 hasIssue "3" @default.
• W2896020168 hasLocation W28960201681 @default.
• W2896020168 hasOpenAccess W2896020168 @default.
• W2896020168 hasPrimaryLocation W28960201681 @default.
• W2896020168 hasRelatedWork W2053161893 @default.
• W2896020168 hasRelatedWork W2765432779 @default.
• W2896020168 hasRelatedWork W2775223914 @default.
• W2896020168 hasRelatedWork W2914394780 @default.
• W2896020168 hasRelatedWork W2943531200 @default.
• W2896020168 hasRelatedWork W3084659464 @default.
• W2896020168 hasRelatedWork W3180754778 @default.
• W2896020168 hasRelatedWork W3210282187 @default.
• W2896020168 hasRelatedWork W4292716524 @default.
• W2896020168 hasRelatedWork W4311056356 @default.
• W2896020168 hasVolume "102" @default.
• W2896020168 isParatext "false" @default.
• W2896020168 isRetracted "false" @default.
• W2896020168 magId "2896020168" @default.
• W2896020168 workType "article" @default.